帕金森病前驱期α-突触核蛋白生物标志物的研究进展  

Advances in biomarkers ofα-synuclein in prodromal Parkinson’s disease

作　　者：张亚珂 王顺[1,2] 王玉琳[1] 白妍[3] ZHANG Yake;WANG Shun;WANG Yulin;BAI Yan(Heilongjiang University of Traditional Chinese Medicine,Harbin 150000,China;The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine,Harbin 150000,China;Heilongjiang Academy of Traditional Chinese Medicine,Harbin 150000,China)

机构地区：[1]黑龙江中医药大学,黑龙江哈尔滨150000 [2]黑龙江中医药大学附属第二医院,黑龙江哈尔滨150000 [3]黑龙江省中医药科学院,黑龙江哈尔滨150000

出　　处：《中国实用神经疾病杂志》2024年第4期519-522,共4页Chinese Journal of Practical Nervous Diseases

基　　金：2022年度中华中医药学会求实项目-中医药临床案例成果库建设专项(编号:QSAL2022-016)。

摘　　要：帕金森病(PD)是最常见的神经退行性疾病之一,临床诊断的PD患者已出现实质性、不可逆的神经退行性病变,临床上通过多巴胺能药物对症治疗并不能阻止疾病进展和降低致残率。近年来,帕金森病研究关口前移,众多研究在其前驱期探索神经保护疗法,以期延缓与阻止疾病进展。在此类型研究中,如何大范围准确筛选、检测、识别PD前驱期患者是目前所面临的难题。α-突触核蛋白是PD的标志性蛋白,本文以α-突触核蛋白为切入点,阐述其在PD发病过程中的重要理论地位,整合近年来已报道的PD前驱期患者脑脊液、组织、粪便中α-突触核蛋白的检测特异性,整理各研究所采用的检测方法及其优缺点,为临床进一步探索该标志物提供参考。Parkinson’s disease(PD)is one of the most common neurodegenerative diseases,but clinically diagnosed PD patients have developed substantial and irreversible neurodegenerative diseases,meanwhile clinical dopaminergic drug symptomatic treatment can not prevent the disease progress and disability rate.Recent years,the research threshold of this disease has moved forward,and neuroprotective therapy has been explored in its prodromal stage in order to delay and prevent the disease from progressing.In this type of exploration,how to accurately screen,detect and identify prodromal patients in large range is a current problem.α-synuclein is the signature protein of PD.In this paper,we has integrated specificity ofα-Syn in cerebrospinal fluid,tissues and stool of PD prodromal patients so as to provide references for further clinical exploration of this marker.

关 键 词：帕金森病 帕金森病前驱期 Α-突触核蛋白 生物标志物 检测特异性 

分 类 号：R742.5[医药卫生—神经病学与精神病学]